Novel microtubule-targeting agent largely avoids neuropathy
In cancer therapy, chemotherapy is the workhorse to immunooncology’s and targeted therapy’s show horses. “There has not been a lot of innovation” in the area of chemotherapy, Gordon Shore told BioWorld Insight. Partly, he said, there are good reasons for the attention lavished on immuno-oncology and targeted therapies. The pathways targeted by those approaches “are where the underlying biology of cancer lies, and where rational intervention makes a lot of sense.” But chemotherapies remain both a market opportunity and an area in need of innovation.